Melisko, Michelle E. http://orcid.org/0000-0002-8729-4667
Assefa, Michael
Hwang, Jimmy
DeLuca, Amy
Park, John W.
Rugo, Hope S.
Funding for this research was provided by:
Merck (A105089)
Pfizer (2005-0811)
Article History
Received: 25 May 2019
Accepted: 29 May 2019
First Online: 6 June 2019
Compliance with ethical standards
:
: Michelle Melisko has received funding for clinical trials (paid to the UC Regents) from: Genentech, Merck, Astra Zeneca, Novartis, Lilly, Puma, Celldex, Galena, Nektar, and Daewha Pharmaceuticals, and honorarium from Agendia. Hope Rugo has received funding (paid to the UC Regents) from Genentech, Pfizer, Merck, Astra Zeneca, Novartis, Lilly, Nektar, Macrogenics, Immunomedics, Odonate, OBI, Seattle Genetics, Eisai, and Daiichi, and travel funding from Daiichi, Mylan, Pfizer, Amgen, Merck and Puma. John Park has stock ownership in Merrimack Pharmaceuticals and is a member of the speaker’s bureau for Genentech and Pfizer. The remaining authors have no conflicts to disclose.
: This manuscript complies with all current laws of the country in which it was performed. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained by all individual participants included in the study and all procedures were performed after obtaining informed consent.